Malaria - Pipeline Review, H1 2018

  • ID: 4540580
  • Report
  • 346 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bharat Biotech Ltd
  • DesignMedix Inc
  • Hager Biosciences LLC
  • Lipocure Ltd
  • Osivax SAS
  • MORE
Malaria - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H1 2018, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights:

This latest pipeline guide Malaria - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 11, 10, 56, 22 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 12, 47 and 34 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bharat Biotech Ltd
  • DesignMedix Inc
  • Hager Biosciences LLC
  • Lipocure Ltd
  • Osivax SAS
  • MORE
Introduction

Malaria - Overview

Malaria - Therapeutics Development

Malaria - Therapeutics Assessment

Malaria - Companies Involved in Therapeutics Development

Malaria - Drug Profiles

Malaria - Dormant Projects

Malaria - Discontinued Products

Malaria - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Malaria - Pipeline by 4SC AG, H1 2018

Malaria - Pipeline by AbbVie Inc, H1 2018

Malaria - Pipeline by Agilvax Inc, H1 2018

Malaria - Pipeline by Akshaya Bio Inc, H1 2018

Malaria - Pipeline by AlfaSigma SpA, H1 2018

Malaria - Pipeline by Allergy Therapeutics Plc, H1 2018

Malaria - Pipeline by Altimmune Inc, H1 2018

Malaria - Pipeline by Artificial Cell Technologies Inc, H1 2018

Malaria - Pipeline by AstraZeneca Plc, H1 2018

Malaria - Pipeline by Bharat Biotech Ltd, H1 2018

Malaria - Pipeline by Cadila Healthcare Ltd, H1 2018

Malaria - Pipeline by Carna Biosciences Inc, H1 2018

Malaria - Pipeline by CEL-SCI Corp, H1 2018

Malaria - Pipeline by Celgene Corp, H1 2018

Malaria - Pipeline by Cilian AG, H1 2018

Malaria - Pipeline by Curevac AG, H1 2018

Malaria - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Malaria - Pipeline by DesignMedix Inc, H1 2018

Malaria - Pipeline by DMG Deutsche Malaria GmbH, H1 2018

Malaria - Pipeline by Eisai Co Ltd, H1 2018

Malaria - Pipeline by Fosun International Ltd, H1 2018

Malaria - Pipeline by GenVec Inc, H1 2018

Malaria - Pipeline by Genzyme Corp, H1 2018

Malaria - Pipeline by GeoVax Labs Inc, H1 2018

Malaria - Pipeline by GlaxoSmithKline Plc, H1 2018

Malaria - Pipeline by Hager Biosciences LLC, H1 2018

Malaria - Pipeline by iBio Inc, H1 2018

Malaria - Pipeline by Ichor Medical Systems Inc, H1 2018

Malaria - Pipeline by ID Pharma Co Ltd, H1 2018

Malaria - Pipeline by Immunovaccine Inc, H1 2018

Malaria - Pipeline by IPCA Laboratories Ltd, H1 2018

Malaria - Pipeline by Kancera AB, H1 2018

Malaria - Pipeline by Kymab Ltd, H1 2018

Malaria - Pipeline by Lipocure Ltd, H1 2018

Malaria - Pipeline by LondonPharma Ltd, H1 2018

Malaria - Pipeline by Marinomed Biotech AG, H1 2018

Malaria - Pipeline by Merck KGaA, H1 2018

Malaria - Pipeline by Microbiotix Inc, H1 2018

Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Malaria - Pipeline by Mymetics Corp, H1 2018

Malaria - Pipeline by Nobelpharma Co Ltd, H1 2018

Malaria - Pipeline by Novartis AG, H1 2018

Malaria - Pipeline by Osivax SAS, H1 2018

Malaria - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Malaria - Pipeline by PaxVax Inc, H1 2018

Malaria - Pipeline by Pfizer Inc, H1 2018

Malaria - Pipeline by Protein Potential LLC, H1 2018

Malaria - Pipeline by Rodos BioTarget GmbH, H1 2018

Malaria - Pipeline by Sanaria Inc, H1 2018

Malaria - Pipeline by Sanofi, H1 2018

Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018

Malaria - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Malaria - Pipeline by Theravectys SA, H1 2018

Malaria - Pipeline by Titan Pharmaceuticals Inc, H1 2018

Malaria - Pipeline by VLP Biotech Inc, H1 2018

Malaria - Pipeline by VLP Therapeutics LLC, H1 2018

Malaria - Dormant Projects, H1 2018

Malaria - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • AbbVie Inc
  • Agilvax Inc
  • Akshaya Bio Inc
  • AlfaSigma SpA
  • Allergy Therapeutics Plc
  • Altimmune Inc
  • Artificial Cell Technologies Inc
  • AstraZeneca Plc
  • Bharat Biotech Ltd
  • Cadila Healthcare Ltd
  • Carna Biosciences Inc
  • CEL-SCI Corp
  • Celgene Corp
  • Cilian AG
  • Curevac AG
  • Daiichi Sankyo Co Ltd
  • DesignMedix Inc
  • DMG Deutsche Malaria GmbH
  • Eisai Co Ltd
  • Fosun International Ltd
  • GenVec Inc
  • Genzyme Corp
  • GeoVax Labs Inc
  • GlaxoSmithKline Plc
  • Hager Biosciences LLC
  • iBio Inc
  • Ichor Medical Systems Inc
  • ID Pharma Co Ltd
  • Immunovaccine Inc
  • IPCA Laboratories Ltd
  • Kancera AB
  • Kymab Ltd
  • Lipocure Ltd
  • LondonPharma Ltd
  • Marinomed Biotech AG
  • Merck KGaA
  • Microbiotix Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mymetics Corp
  • Nobelpharma Co Ltd
  • Novartis AG
  • Osivax SAS
  • Otsuka Holdings Co Ltd
  • PaxVax Inc
  • Pfizer Inc
  • Protein Potential LLC
  • Rodos BioTarget GmbH
  • Sanaria Inc
  • Sanofi
  • SBI Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Theravectys SA
  • Titan Pharmaceuticals Inc
  • VLP Biotech Inc
  • VLP Therapeutics LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll